Valuation: SurModics

Market Cap 427M 373M 351M 320M 601M 40.85B 601M 4.21B 1.63B 20.86B 1.6B 1.57B 67.26B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 367M 345M 315M 592M 40.2B 592M 4.14B 1.6B 20.53B 1.58B 1.54B 66.18B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
58.95
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 2025-11-18
Director of Finance/CFO 53 2025-11-18
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 2025-11-18
Director/Board Member 53 2025-11-18
Date Insider Type Main position Quantity % Market Cap. Importance
11/19/25 Issuer sale

Executive/Senior Manager

171,148 1.1970%
11/19/25 Issuer sale

Director

35,847 0.2507%
11/19/25 Issuer sale

Controller/Auditor

24,311 0.1700%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+33.60%+32.49% 615M
+0.69%+1.63%-24.10%+5.64% 178B
-1.07%-3.18%-4.07%+13.08% 117B
-0.65%-2.74%+8.88%+69.09% 60.39B
+1.27%-1.57%-1.90%-31.00% 49.22B
-0.22%+1.23%+7.80%+45.79% 48.02B
+0.40%+3.56%+28.80%+2.32% 33.65B
+7.73%+7.23% - - 28.04B
+2.57%+1.67%+47.13%-0.38% 25.46B
+2.38%+8.63%+11.66%-10.18% 22.5B
Average +1.34%+1.50%+11.98%+14.10% 56.34B
Weighted average by Cap. +0.64%+0.39%-2.81%+13.53%

Financials

2023 2024
Net sales 133M 116M 109M 99.38M 187M 12.67B 187M 1.31B 504M 6.47B 498M 487M 20.87B 126M 110M 104M 94.5M 177M 12.05B 177M 1.24B 480M 6.16B 473M 463M 19.84B
Net income -1.54M -1.34M -1.26M -1.15M -2.16M -147M -2.16M -15.14M -5.84M -74.99M -5.77M -5.64M -242M -11.54M -10.09M -9.48M -8.65M -16.24M -1.1B -16.24M -114M -43.9M -563M -43.34M -42.39M -1.82B
Net Debt -12.1M -10.58M -9.94M -9.07M -17.02M -1.16B -17.03M -119M -46.03M -591M -45.44M -44.45M -1.9B -6.87M -6M -5.64M -5.15M -9.66M -657M -9.67M -67.72M -26.13M -335M -25.8M -25.23M -1.08B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!